Overview
Emerging psychedelic biotech developing novel ibogaine-derived compounds for addiction treatment and neurological repair without the cardiac risks of ibogaine itself. Their pipeline targets opioid use disorder and traumatic brain injury.
More in Psychedelics
Latest industry news
China Performs World's First Commercial BCI Implant, Marking a Pivotal Moment in the Global Brain-Computer Interface Race
2026-07-16 · Industry
NIH Confirms Brain-Computer Device Restores Speech in Human Patient
2026-07-15 · Research
Neurovalens Wins FDA Approval for Wearable PTSD Therapy Aimed at US Veterans
2026-07-14 · Policy
BRYM Raises €650K to Build Wearable Neurofeedback Platform for Consumer and Clinical Markets
2026-07-13 · Funding
Company details
Category
🍄 Psychedelics
Location
San Francisco, CA, USA
Funding
Seed · $8M
Website
camposantotherapeutics.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →